MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application
|ClinicalTrials.gov Identifier: NCT00223548|
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : September 22, 2005
|Condition or disease||Intervention/treatment||Phase|
|Chronic Renal Insufficiency Serum Creatinine Concentration Contrast Media Exposition||Drug: sodium 2-mercaptoethane sulfonate||Phase 2|
Contrast-induced nephropathy remains a common complication of radiographic precedures. Pretreatment with Mesna (Sodium 2-mercaptoethane sulfonate) in combination with sodium chloride is more protective than sodium chloride alone in animal models of acute renal failure.
The aim of this study is therefore to determine laboratory and clinical benefit of MESNA, as an adjunct to saline hydration, in patients with known renal impairment receiving contrast media.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||106 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||MESNA Zur Prophylaxe Der Kontrastmittel-Induzierten Nephropathie|
|Study Start Date :||October 2002|
|Estimated Study Completion Date :||December 2004|
- Contrast-agent associated nephrotoxicity was defined as an increase in serum creatinine concentration >0.5 mg/dl (44 umol/l) of the baseline value 48 h after administration of the contrast media.
- Need for dialysis after the administration of contrast media.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00223548
|Division of Nephrology, University of Ulm|
|Ulm, Germany, 89081|
|Principal Investigator:||Frieder Keller, M.D.||Division of Nephrology, University Hospital Ulm|
|Principal Investigator:||Frieder Keller, M.D.||Division of Nephrology, University Hospital of Ulm|